莎普爱思：去氧肾上腺素酮咯酸溶液临床试验获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for a clinical trial of a new drug, which is aimed at maintaining pupil dilation during cataract surgery and alleviating postoperative eye pain [1] Group 1 - The drug in question is deoxycorticosterone ketone solution, which is specifically indicated for use during cataract surgery or artificial lens replacement [1] - The approval is significant as it allows the company to proceed with clinical trials, potentially leading to a new product in the ophthalmology market [1]